Preventative effect of a flavonoid, enzymatically modified isoquercitrin on ocular symptoms of Japanese cedar pollinosis
Hirano T, Kawai M, Arimitsu J, Ogata A, Tanaka T
Published in Allergology International
Methodology
Parallel-group, double-blind, placebo-controlled trial of 100 mg/day EMIQ for 8 weeks, started 4 weeks before pollen release
Key Findings
Ocular symptom plus medication score was significantly lower with EMIQ; ocular symptom and congestion scores improved at weeks 5-6. No significant difference in nasal symptoms. Serum quercetin derivatives rose significantly.
Conclusions
Pre-season EMIQ reduced ocular but not nasal symptoms of cedar pollinosis.
Limitations
Small sample (n=24), short duration, benefits limited to eye symptoms.
Supplements Studied
ocular symptom + medication score for the EMIQ group was significantly lower (p < 0.05) than that of the placebo group
Related Health Concerns
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.